Herpes Zoster bei entzündlich-rheumatischen Erkrankungen

Zusammenfassung

Der Herpes Zoster ist eine häufige Viruserkrankung, die meist nach einer jahrzehntelangen Latenz durch eine Reaktivierung einer Varizella-Zoster-Primärinfektion auftritt. Besonders betroffen sind ältere Personen sowie solche mit geschwächtem Immunsystem. Während der akuten Phase zeigen sich dermatombezogene Schmerzen sowie ein papulovesikuläres Exanthem. Die am häufigsten auftretende Komplikation ist die sehr schmerzhafte Post-Zoster-Neuralgie, die über Monate bis zu Jahren anhalten kann. Zur Prävention steht ein Totimpfstoff zur Verfügung, der von der Ständigen Impfkommission (STIKO) als Indikationsimpfung für Personen mit einem entsprechenden Risikoprofil ab dem 50. Lebensjahr sowie als Standardimpfung ab dem 60. Lebensjahr empfohlen wird.

Abstract

Herpes zoster is a viral disease that commonly occurs after a prolonged period of latency due to reactivation of an initial varicella zoster infection. The disease mainly affects older adults and those with impaired immune systems. In the acute phase, individuals experience dermatome-linked pain and papulovesicular rash. The primary complication is excruciating postherpetic neuralgia, which can last several months to years. For precautionary purposes, an inactivated vaccine is available. This vaccine is recommended by the German Standing Committee on Vaccination (STIKO) for individuals with an increased risk profile starting at 50 years of age and as a routine vaccination for individuals aged 60 and older.

Schlüsselwörter

Herpes Zoster - Post-Zoster-Neuralgie - Immunmodulation - Autoimmunerkrankung - Entzündung

Key words

herpes zoster - postherpetic neuralgia - immunomodulation - autoimmune disease - inflammation

Publication History

Article published online:
06 February 2024

• Literatur

• 1 Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology 2013; 81: 928-930 DOI: 10.1212/WNL.0b013e3182a3516e.
• 2 Cohen JI. Herpes Zoster. N Engl J Med 2013; 369: 255-263 DOI: 10.1056/NEJMcp1302674.
• 3 Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4: e004833-e004833 DOI: 10.1136/bmjopen-2014-004833.
• 4 Gross GE, Eisert L, Doerr HW. et al. S2k-Leitlinie zur Diagnostik und Therapie des Zoster und der Postzosterneuralgie. JDDG J Dtsch Dermatol Ges 2020; 18: 55-79 DOI: 10.1111/ddg.14013_g.
• 5 Schmader K. Herpes Zoster. Ann Intern Med 2018; 169: ITC17 DOI: 10.7326/AITC201808070.
• 6 Sundriyal D, Kapoor R, Kumar N. et al Multidermatomal herpes zoster. Case Rep 2014; 2014 bcr2014205024–bcr2014205024 DOI: 10.1136/bcr-2014-205024.
• 7 Forbes HJ, Thomas SL, Smeeth L. et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016; 157: 30-54 DOI: 10.1097/j.pain.0000000000000307.
• 8 Oster G, Harding G, Dukes E. et al. Pain, Medication Use, and Health-Related Quality of Life in Older Persons With Postherpetic Neuralgia: Results From a Population-Based Survey. J Pain 2005; 6: 356-363 DOI: 10.1016/j.jpain.2005.01.359.
• 9 Johnson RW, Bouhassira D, Kassianos G. et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010; 8: 37 DOI: 10.1186/1741-7015-8-37.
• 10 Niederer RL, Meyer JJ, Liu K. et al. Herpes Zoster Ophthalmicus Clinical Presentation and Risk Factors for Loss of Vision. Am J Ophthalmol 2021; 226: 83-89 DOI: 10.1016/j.ajo.2021.02.002.
• 11 Schoenberger SD, Kim SJ, Thorne JE. et al. Diagnosis and Treatment of Acute Retinal Necrosis. Ophthalmology 2017; 124: 382-392 DOI: 10.1016/j.ophtha.2016.11.007.
• 12 Monsanto R, Bittencourt A, Bobato Neto N. et al. Treatment and Prognosis of Facial Palsy on Ramsay Hunt Syndrome: Results Based on a Review of the Literature. Int Arch Otorhinolaryngol 2016; 20: 394-400 DOI: 10.1055/s-0036-1584267.
• 13 Shim HJ, Jung H, Park DC. et al. Ramsay Hunt syndrome with multicranial nerve involvement. Acta Otolaryngol (Stockh) 2011; 131: 210-215 DOI: 10.3109/00016489.2010.520167.
• 14 Yanni EA, Ferreira G, Guennec M. et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012. BMJ Open 2018; 8: e020528 DOI: 10.1136/bmjopen-2017-020528.
• 15 Gupta G, Lautenbach E, Lewis JD. Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2006; 4: 1483-1490 DOI: 10.1016/j.cgh.2006.09.019.
• 16 Yun H, Yang S, Chen L. et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheumatol 2016; 68: 2328-2337 DOI: 10.1002/art.39670.
• 17 Forbes HJ, Bhaskaran K, Thomas SL. et al. Quantification of risk factors for herpes zoster: population based case-control study. BMJ 2014; 348: g2911 DOI: 10.1136/bmj.g2911.
• 18 Ehrenstein B. Diagnostik, Therapie und Prophylaxe des Herpes zoster. Z Für Rheumatol 2020; 79: 1009-1017 DOI: 10.1007/s00393-020-00915-y.
• 19 Galloway J, Raine T, Rivett L. et al. Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clin Exp Rheumatol 2021; DOI: 10.55563/clinexprheumatol/0jdyse.
• 20 Marra F, Lo E, Kalashnikov V. et al. Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infect Dis 2016; 3: ofw205 DOI: 10.1093/ofid/ofw205.
• 21 Redeker I, Albrecht K, Kekow J. et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis 2022; 81: 41-47 DOI: 10.1136/annrheumdis-2021-220651.
• 22 Dworkin RH, Barbano RL, Tyring SK. et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009; 142: 209-217 DOI: 10.1016/j.pain.2008.12.022.
• 23 Rodríguez MJ, Díaz S, Vera-Llonch M. et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007; 23: 2585-2596 DOI: 10.1185/030079907X233151.
• 24 Rowbotham M, Harden N, Stacey B. et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-1842 DOI: 10.1001/jama.280.21.1837.
• 25 Wang S-L, Wang H, Nie H-Y. et al. The efficacy of pregabalin for acute pain control in herpetic neuralgia patients: A meta-analysis. Medicine (Baltimore) 2017; 96: e9167 DOI: 10.1097/MD.0000000000009167.
• 26 Wiffen PJ, Derry S, Bell RF. et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6: CD007938 DOI: 10.1002/14651858.CD007938.pub4.
• 27 Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 2000; 16: S49-55 DOI: 10.1097/00002508-200006001-00009.
• 28 Kennedy WR, Vanhove GF, Lu S-P. et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010; 11: 579-587 DOI: 10.1016/j.jpain.2009.09.019.
• 29 Derry S, Wiffen PJ, Moore RA. et al. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev 2014; 2014: CD010958 DOI: 10.1002/14651858.CD010958.pub2.
• 30 Khaliq W, Alam S, Puri NK. Topical lidocaine for the treatment of postherpetic neuralgia. In: The Cochrane Collaboration, Hrsg. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007: CD004846 pub2
• 31 RKI – RKI-Ratgeber – Windpocken (Varizellen), Gürtelrose (Herpes zoster). Im Internet https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Varizellen.html#doc2374554bodyText14 Stand: 09.10.2023
• 32 Cunningham AL, Lal H, Kovac M. et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016; 375: 1019-1032 DOI: 10.1056/NEJMoa1603800.
• 33 Lal H, Cunningham AL, Godeaux O. et al. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. N Engl J Med 2015; 372: 2087-2096 DOI: 10.1056/NEJMoa1501184.
• 34 Dagnew AF, Ilhan O, Lee W-S. et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 2019; 19: 988-1000 DOI: 10.1016/S1473-3099(19)30163-X.
• 35 Vink P, Ramon Torrell JM, Sanchez Fructuoso A. et al. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clin Infect Dis 2020; 70: 181-190 DOI: 10.1093/cid/ciz177.
• 36 Vink P, Delgado Mingorance I, Maximiano Alonso C. et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer 2019; 125: 1301-1312 DOI: 10.1002/cncr.31909.
• 37 Übersicht über Shingrix und warum es in der EU zugelassen ist https://www.ema.europa.eu/en/documents/overview/shingrix-epar-medicine-overview_de.pdf (Stand 2023-10-17)
• 38 Robert-Koch-Institute. Wissenschaftliche Begründung für die Entscheidung, die Herpeszoster-Lebendimpfung nicht als Standardimpfung zu empfehlen (https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2017/Ausgaben/36_17.pdf?__blob=publicationFile, abgerufen am 2023-10-17)
• 39 Varan Ö, Babaoğlu H, Göker B. Associations between Depressive Disorders and Inflammatory Rheumatic Diseases. Curr Top Med Chem 2018; 18: 1395–1401. DOI: 10.2174/1568026618666180516100805. PMID: 29766809